INDIAN PHARMACEUTICAL ALLIANCE
India and Russia at 25: From trusted partners to global shapers
India and Russia's strategic partnership, formalized 25 years ago, has evolved into a robust alliance built on trust and shared purpose. This enduring relationship, marked by strong political, defense, and economic cooperation, continues to adapt to global shifts, with both nations aiming for deeper collaboration in technology, energy, and cultural exchange for the next quarter-century.
Indian firms explore localisation of pharma production in Russia
The Russian market is attracting growing interest from Indian pharmaceutical companies exploring opportunities to establish production facilities across various regions of the country. This was announced by Moscow Government Minister and Head of the Department for External Economic and International Relations, Sergey Cheremin, during the " Russia-India. Mutual Efficiency" forum.
Canada may need India now more than ever as trade risks mount
Canada is seeking to diversify its trade and strategic partnerships, particularly with India, to mitigate economic pressures from the United States and China. Foreign Minister Anita Anand is leading efforts to strengthen ties with India, focusing on trade, technology, energy, and security, aiming for a more stable economic future.
Nagaland University-led study finds tea blossoms rich in health-boosting compounds
A new study reveals tea blossoms hold significant health potential. These flowers, usually discarded, are packed with beneficial compounds. Researchers believe they can be used for natural health supplements and drinks. This discovery could reduce agricultural waste and boost rural economies. India is poised to become a leader in these new plant-based products.
Just the booster pill Indian pharma needs
Indian Pharma must look at strengthening its presence in established markets in Latin America, China, Russia, Africa and East Europe. This is a timely pill for industry to take.
Indian Pharmaceutical Alliance appoints Zydus Lifesciences MD Sharvil Patel as new president
The Indian Pharmaceutical Alliance (IPA) has appointed Sharvil Patel of Zydus Lifesciences as its new President, with Glenn Saldanha of Glenmark as Vice President. This leadership transition occurs as the industry navigates GST reforms and strengthens its global position in specialty medicines. The new team aims to drive innovation, patient access, and quality healthcare solutions.
- Go To Page 1
IPA names Zydus Lifesciences MD Sharvil Patel as President
Sharvil Patel is the new president of the Indian Pharmaceutical Alliance. He takes over from Samir Mehta. Glenn Saldanha becomes the vice president. The IPA represents 23 national pharmaceutical companies. The new team will build on reforms and breakthroughs. They will focus on innovation, patient access, and quality in healthcare.
US tariffs on India a wrong approach: Phil Murphy, New Jersey Governor
New Jersey has over 60 Indian life sciences companies including Biocon, BDR Pharma, Lupin, Meteoric Pharma, Dr Reddy's Labs, Rubicon Research, Cipla, Aurobindo and Enzene Biosciences. Also, New Jersey has the highest concentration of Indian-Americans in the US, making it an ideal landing spot for Indian businesses.
'Indian generics safe, tariffs unwise': Indian pharma association hits back after US tariff concerns
India's pharmaceutical industry, through the IPA, strongly countered US concerns regarding the quality of generic medicines, warning that tariffs would jeopardize America's drug security and increase reliance on China. The IPA cited FDA reports and independent testing affirming Indian facilities' high standards, highlighting billions saved for the US healthcare system.
US tariff a bitter pill for Indian pharma
Donald Trump's tariffs will impact Indian medicine exports. This policy targets branded and patented drugs. Indian generic drug makers face challenges. They must explore markets beyond the United States. China offers a destination for Indian pharma companies. This shift will alter global drug industry dynamics. India needs to adapt its export strategy.
Bitter pill, not poison: 100% Trump tariff on imported meds can act as smelling salt for Indian pharma
Trump's 100% tariff on imported branded drugs poses limited immediate threat to Indian pharma, as it excludes generics, India's main US export. This policy signals a US push for domestic production, prompting Indian firms to diversify markets, expand US manufacturing, and innovate to secure future global leadership.
Just like bad medicine...Trump tariff pricks again; India not seen badly hit by US’ latest salvo
US President Trump’s 100% tariff on pharmaceutical products targets only branded and patented drugs, leaving India’s generic exports largely unaffected, experts say. The tariff, effective October 1, spooked pharma stocks but poses minimal immediate risk. India exported $9.8 billion in pharma to the US in FY25. Tariffs on furniture and trucks may benefit India, while bilateral trade talks continue.
Trump's 100% tariff on pharma will not impact generic makers, says Indian Pharma Alliance
Donald Trump's proposed 100% tariffs on patented drugs from October 2025 are unlikely to immediately impact Indian pharma exports, which primarily consist of generic medicines. Experts believe the focus should shift towards cost-efficiency in bulk drugs and investment in complex generics and biosimilars.
Trump delivers another bitter tariff pill. Who’s set to bite the dust?
A new tariff announced by President Trump will impose a 100% levy on patented pharmaceuticals entering the U.S. from October 1, 2025, unless companies have manufacturing facilities in the country. This policy raises uncertainties about which drugs will be affected and challenges the Indian pharmaceutical sector, which significantly contributes to the U.S. market—supplying 47% of generics and saving the U.S. healthcare system $219 billion in 2022.
India’s cheap birth control pills in US could vanish under Trump’s 250% tariff threat
Donald Trump's tariff threat jeopardizes affordable Indian medicines in the US. Birth control pills, hypertension, and depression treatments are most vulnerable. India, the world's pharmacy, faces potential export losses. Analysts foresee price hikes and supply chain disruptions. Indian firms may struggle to absorb tariffs. The US aims to boost domestic drug production. This move risks higher drug prices for Americans.
"Transformative shift in India's healthcare": Pharma alliance lauds GST reforms ahead of implementation
The Indian Pharmaceutical Alliance lauds the upcoming GST reforms, effective Monday, as a transformative step towards affordable healthcare. Prime Minister Modi's initiative reduces GST on most medicines from 12% to 5%, with complete exemption for 36 critical life-saving drugs.
Healthcare set to be more affordable as new GST rate kicks in from Sep 22: Pharma industry
From September 22, medicines and medical devices in India will become cheaper under new GST rates, making healthcare more affordable, say industry experts. Most drugs’ GST drops from 12% to 5%, while 36 critical life-saving medicines are fully exempt. Tax slabs on insurance, glucometers, and spectacles are also rationalised, easing costs for patients and improving access to essential care.
VTB Bank’s two-decade journey in India as trade and finance evolve
VTB Bank, the first Russian bank in India, has significantly expanded its operations since 2005, facilitating growing India-Russia trade. With a focus on direct rupee-rouble transactions and support for Russian firms, VTB is enhancing financial infrastructure. The bank's strategic expansion includes new offices and online services to streamline business operations between the two nations, fostering a stronger economic partnership.
In major move, patent of Novartis' blockbuster cardiac drug revoked by India
The Indian Patent Office revoked Novartis' patent for Vymada, a heart failure drug, citing a lack of novelty and inventive step. This decision paves the way for generic versions, potentially lowering treatment costs for Indian patients. Domestic pharmaceutical companies had challenged the patent, arguing it violated Section 3(d) of the Patents Act, which prevents 'evergreening'.
Why did Elon Musk not attend Trump's dinner with high-profile tech CEOs? Tesla CEO has this to say
President Trump held a big White House dinner with top tech CEOs to talk about AI and U.S. investments. Leaders like Mark Zuckerberg, Tim Cook, and Bill Gates joined the event. Elon Musk was missing, saying he could not attend. The meeting showed how Silicon Valley is now working more closely with Trump’s administration.
Crucial drugs to be more affordable after GST cut
The government has significantly reduced GST rates on 41 highly priced medicines, including those for cancer, rare diseases, and heart conditions, aiming to make healthcare more affordable. Key drugs like Risdiplam and daratumumab will now have zero GST, benefiting patients with spinal muscular atrophy and multiple myeloma.
GST cut on drugs, medical devices to provide relief to patients: Industry players
The government is reducing GST on medicines and medical devices. Lifesaving drugs are exempt. This action will help patients and families. It will also make healthcare more affordable. Sudarshan Jain and Anil Matai welcome the changes. Ameera Shah and Shobana Kamineni also support the move. Himanshu Baid says it will improve access to medical technologies.
ET MSME Awards 2025: Are you powering India’s export growth? Nominate yourself for the Top Exporter Award
The ET MSME Awards celebrate the country’s top exporters and their global achievements.
Trump plans 200% tariff on imported drugs, raising risk of higher US prices and shortages
US President Donald Trump has threatened pharmaceutical import tariffs of up to 200 per cent, a move that experts warn could raise drug costs and create shortages across the United States. Analysts say stockpiling may delay pain until 2027, but generics and low-income patients would suffer most. India’s exporters have been excluded from immediate enforcement. Courts have questioned the administration’s authority and the issue may reach the Supreme Court. The policy forces a choice between reshoring production and preserving affordable access.
Trump's bright anti-China idea begins to dim
The Quad, a strategic alliance between the US, India, Japan and Australia, faces internal strain due to Trump's unpredictable foreign policy. His cancellation of the India summit and strained relationships with key leaders like Modi and Albanese have caused unease. As members independently engage with China, the Quad's future as a united front against Chinese assertiveness is undermined.
Time to turn challenges into advantage, strengthen MSMEs & agriculture, says CII President Memani on US Tariffs
The Confederation of Indian Industry (CII) suggests diversifying trade, promoting Indian MSMEs, and strengthening agriculture to combat global uncertainties caused by US tariffs. CII President Rajiv Memani emphasizes the need for Indian industry to invest in quality, branding, and technology. He believes this will make Indian products and services indispensable worldwide, turning challenges into opportunities.
Trump’s 50% tariffs go live: What they mean for India and the way forward
The sectors that are likely to be impacted the most include gems and jewellery, textiles and apparel, auto components, steel and metal products, shrimp and seafood, and organic chemicals.
India’s digital edge, China’s manufacturing, Russia’s energy: A new axis of global growth
Prime Minister Modi's upcoming visit to China after seven years signals a potential strategic shift, fostering a new economic partnership with China and Russia. This triad, boasting a significant portion of global GDP, exports, and reserves, aims to reshape trade routes and challenge the dollar's dominance.
China hoarding its tech riches fiercely
As Narendra Modi visits China, partnership deals between Indian and Chinese companies face delays. China is carefully vetting technology transfer terms, impacting sectors like appliances and auto components. Haier's stake sale in its Indian unit is held up. PG Electroplast's compressor project also faces delays. These hurdles affect Indian firms reliant on Chinese technology and components.
Load More
